Drug safety of NSAIDs and COX-2 inhibitors;Zur arzneimittelsicherheit von NSAR und COX-2-hemmern

Medizinische Monatsschrift fur Pharmazeuten

Volumn 29, Issue 4, 2006, Pages 122-128

  Herdegen, Thomas ^a,b   Fauler, Joachim ^a,c  

^a Campus Kiel ^*

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRONE; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PARECOXIB; PIROXICAM; ROFECOXIB; VALDECOXIB;

ASTHMA; CARDIOVASCULAR RISK; DIGESTIVE SYSTEM INJURY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION;

EID: 33645919611     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Hippisłey-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366.
2. Singh G, Mithal A, Triadafilopoulos G. Both selective cox-2 inhibitors and non selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Annals Rheum Dis 2005;64(Suppl III):85.
3. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, rheumatism, and aging medical information system. J Rheumatol Suppl 1998;51:8-16.
4. Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283-91.
5. Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98: 1725-33.
6. Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003;139: 539-46.
7. Martina S, Vesta K, Ripley T. Etoricoxib: A highly selective COX-2 inhibitor. Ann Pharmacother 2005;39:854-62.
8. Ramey DR, Watson DJ, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21: 715-22.
9. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
10. Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004;117:100-6.
11. Müller P. Simon B. Kurzzeitige Schmerzmittel - Risiko für Magen und Darm, http://kassenarzt.dgmedien-ar.de 2005.
12. Freestone S, Bello A. Comparison of the effects of celecoxib, meloxicam, and nimesulide on platelet function in healthy subjects. Ann Rheum Dis 2005;64(Suppl III):495.
13. Schrör K. Kardiovaskuläre Risiken von COX-2-Hemmern. Dtsch Med Wochenschr 2004;129:2653-6.
14. Hegi TR, Bombeli T, Seifert B, et al. Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. Br J Anaesth 2004;92:523-31.
15. Catella-Lawson F, Reilly MP, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
16. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295-301.
17. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004;33:1-6.
18. Yaksh TL, Dirig DM, Conway CM, et al. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001;21:5847-53.
19. Zeilhofer HU. The glycinergic control of spinal pain processing. Cell Mol Life Sci 2005;62:2027-35.
20. Hunot S, Vila M, Teismann P, et al. JNK-mediated induction of cyclooxygenase-2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2004;101:665-70.
21. Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med 2001;344:142.
22. El Miedany YM, Youssef SS, Ahmed I, et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cyclooxygenase-2 inhibitor, in inflammatory bowel disease. Ann Rheum Dis 2005;64(Suppl III):321.
23. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47-51.
24. Stiefelhagen P. Glykoprotein-IIb/IIIa-Rezeptorantagonisten als Monooder Kombinationstherapie. Arzneimitteltherapie 2004;22:346-7.
25. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840-55.
26. Hallak A, Alon-Baron L, Shamir R, et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003;48:1998-2002.
27. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
28. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
29. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
30. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-92.
31. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
32. White WB, Strand V, Roberts R, et al. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus non-steroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004;11:244-50.
33. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71.
34. Brinker A, Goldkind L, Bonnel R, et al. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 2004;21:479-84.
35. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
36. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
37. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-64.
38. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and non-steroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8.
39. Wieckhorst A, Tiroke A, Lins M, et al. [Acute coronary syndrome after diclofenac induced coronary spasm]. Z Kardiol 2005;94:274-9.
40. Fischer LM, Schlienger RG, Matter CM, et al. Current use of non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 2005;25:503-10.
41. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.
42. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by non-steroidal anti-inflammatory drugs. Circulation 2003;108:1191-5.
43. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
44. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
45. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005;11:1795-1804.
46. Stichtenoth DO, Froelich JC. COX-2 and the kidneys. Curr Pharm Des 2000;6:737-53.
47. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004;24: 246-55.
48. Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 2005;96:e1-6.
49. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46: 500-7.
50. Castaneda-Hernández G, Lozano-Cuenca J, Granados-Soto V. Lumiracoxib, a selective cox-2 inhibitor, is also able to produce peripheral analgesia by activation of the nitric oxide-cyclic GMP-potassium channel pathway. Ann Rheum Dis 2005;64(Suppl III):132.
51. Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004;177:235-43.
52. 2 inhibition. Ann Rheum Dis 2005;64(Suppl III):496.
53. Masterbergen SC, Jansen NWD, Bijlsma JWJ, et al. Direct effects of different commonly used NSAIDs on human osteoarthritic cartilage. Ann Rheum Dis 2005;64(Suppl III):148.